epiPancancer

Thanks to the development of our epiPancancer, we can detect up to 33 different types of cancer. Current biomarkers lack sensitivity and specificity to detect cancer early. Available biomarkers and diagnostic methods are invasive and cannot be used for follow-up of a healthy population.

Our scientists conducted multiple cancer blood tests to investigate DNA methylation results from normal tissues, blood, and cancer from thousands of people and used proprietary methods to discover unique methylation profiles that are categorically different between each tissue type.  Our new Binary Categorical Differentiation (BCD) method identifies stark differences between cancer cells and normal cells.